Herein, we describe the case of a 35-year-old man who engages in sex with men and presented with newly diagnosed HIV-1, serological markers for acute hepatitis B and progression to chronic hepatitis B infection (HBsAg+>6months, high alanine aminotransferase levels and moderate hepatitis as indicated by liver biopsy)

Herein, we describe the case of a 35-year-old man who engages in sex with men and presented with newly diagnosed HIV-1, serological markers for acute hepatitis B and progression to chronic hepatitis B infection (HBsAg+>6months, high alanine aminotransferase levels and moderate hepatitis as indicated by liver biopsy). infection (HBsAg+ > 6 months, high alanine aminotransferase levels and moderate hepatitis as indicated by liver biopsy). Lacking indication of antiretroviral treatment (CD4 768 cells/mm3), he was treated with pegylated-interferon alpha2b (1.5 mg/kg/week) by subcutaneous injection for 48 weeks. Twelve weeks after treatment, the patient presented HBeAg seroconversion to anti-HBe. At the end of 48 weeks, he presented HBsAg seroconversion to anti-HBs. One year after treatment, the patient maintained sustained virological response (undetectable HBV-DNA). The initiation of antiretroviral therapy with nucleosides and nucleotides is recommended earlier for coinfected individuals. However, this report emphasizes that pegylated interferon remains an important therapeutic strategy to be considered for selected patients, in whom the initiation of HAART may be delayed. Keywords:HIV, Hepatitis B, HBsAg, Peginterferon == Background == Worldwide, an estimated two billion people have been infected with the hepatitis B virus (HBV), more than 350 million have chronic liver infection and 34 NVS-PAK1-1 million live with the human immunodeficiency virus (HIV) infection [1,2]. The prevalence of hepatitis B in HIV-infected individuals ranges from 6 to 14%, with higher rates in regions where HBV is endemic, such as Africa and Asia [1,3]. Concurrent infection of HIV with HBV occurs because of the overlapping routes of transmission, particularly sexual and parenteral (injecting drug use and blood transfusion). In Brazil, the prevalence of coinfection ranges from 5.3 to 24.3% with significant regional differences NVS-PAK1-1 [4]. The western Amazon is considered highly endemic for hepatitis B, in particular because of the coinfection with hepatitis Delta virus (HDV) [1]. In addition, a recent population-based prevalence study in Brazilian state capitals showed that all geographical regions were considered of low endemicity [5]. Acute hepatitis B patients with HIV infection have six times greater risk of developing chronic hepatitis B, with higher viral replication, rapid progression to end-stage liver disease and shorter survival [6]. The coinfection is also associated with poor response to hepatitis B treatment with interferon-alpha, lower rates of HBeAg seroconversion to anti-HBe and HBsAg to anti-HBs, and greater liver toxicity using the antiretroviral therapy [7-10]. Since the introduction of highly active antiretroviral therapy (HAART), liver disease has emerged as an important cause of morbidity and mortality in HIV-infected individuals. Treatment of chronic hepatitis B is based on the use of pegylated interferon or nucleosides and nucleotides polymerase inhibitors. The international guidelines recommend the use of pegylated interferon for the treatment of HBeAg positive coinfected patients that are non-cirrhotic and with no indication for antiretroviral therapy, with limited treatment duration and probably greater chance of viral suppression after discontinuation [11,12]. == Case presentation == We report the case of a 35-year-old male patient who engages in sexual activity with men, followed in the Campinas Reference Center for Sexually Transmitted Diseases/AIDS since January 2009, with newly diagnosed HIV-1 and the following serological markers for hepatitis B: surface antigen positive (HBsAg+), hepatitis Beantigen positive (HBeAg+), antibodies to hepatitis B core antigen positive (anti-HBc IgM+, anti-HBc IgG+), anti-hepatitis Beantibody negative (anti-HBe-), and anti-hepatitis B surface antigen antibody negative (anti-HBs-). He had a steady partner who presented a diagnosis of hepatitis B with seroconversion to anti-HBs + about four months before the start of the monitoring service and HIV-1 negative at diagnosis of the patient, with seroconversion to HIV-1 positive in 2010 2010. On physical examination, the patient was in good general condition and his body mass index was 24 kg/m2. His liver was palpable at 2 cm from the right costal margin and his spleen was palpable at 2 cm from the left costal margin. He had no stigmata of chronic liver disease. In February 2009, CD4+ lymphocyte (CD4) count was 718 cells/mm3, HIV-1 viral load (VL) was 9399 copies/mL, aspartate aminotransferase (AST) was 347 IU/mL, alanine aminotransferase (ALT) 604 IU/mL, HBsAg+, HBeAg+, anti-HBc IgG+, anti-HBc IgM+, anti-HBe-, anti-HBs-, antibody for hepatitis C virus (HCV) negative, and antibody for hepatitis A (HAV) IgG+, IgM- (Table1). The biochemical liver function test values Rabbit Polyclonal to APOBEC4 were normal. Upper endoscopy showed gastroduodenitis withH. pyloripositive and total abdominal ultrasound showed no abnormality. == Table 1. == Laboratory tests performed during follow-up The patient was classified into the first stage of HIV infection (A1), according to the Centers for Disease Control and Prevention (CDC) criteria NVS-PAK1-1 and acute HBV infection. Then, it was decided to monitor the hepatitis B progress and not initiate antiretroviral therapy. After eight months of follow-up, the patient had the next laboratory tests outcomes: Compact disc4 768 cells/mm3, VL 3746 copies/mL, AST 101 IU/mL, ALT 136 IU/mL, HBsAg+, HBeAg+, anti-HBc IgG+, anti-HBc IgM-, anti-HBe-, and anti-HBs- (Desk1). When chronic hepatitis B (HBsAg+ > six months) was verified, a liver organ biopsy was performed leading to METAVIR rating F2A2. Because.

---